IXICO PLC — Remuneration Information 2017

Feb 9, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 3797W

IXICO plc

09 February 2017

9 February 2017

IXICO plc

("IXICO" or the "Company")

Share option grant to Directors

IXICO plc (AIM: IXI) ('IXICO' or the 'Company'), the brain health company, today announces that on 7 February 2017 the Remuneration Committee agreed to grant options to the Company's Executive Directors and employees in accordance with the rules of the Company's EMI Share Option Plan 2014(the 'Plan') exercisable at a price of 36.5p.

The award of options under the Plan are over the ordinary shares in the Company and are subject to performance conditions. The options will vest upon the achievement of strategic corporate goals in respect of commercialisation of the Company's products and/or services or a significant corporate development transaction within three years of the date of grant.

The total number of options being issued at this time is 1,044,698. The following table sets out the details of the options that have been granted to the Executive Directors:

Name of Director	Number of options granted	Total number of options held	Percentage of issued share capital under option
Giulio Cerroni	676,582	676,582	2.5%
Derek Hill	80,000	540,236	2.0%
Susan Lowther	80,000	490,196	1.8%

For further information please contact:

IXICO plc Charles Spicer, Non-Executive Chairman Susan Lowther, Chief Financial Officer and Company Secretary	Tel: +44 20 3763 7499
Shore Capital (Nomad and Broker) Bidhi Bhoma / Edward Mansfield		Tel: +44 20 7408 4090
FTI Consulting Limited (Investor Relations) Simon Conway/Mo Noonan/Matthew Moss		Tel: +44 20 3727 1000

About IXICO

IXICO's innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions.  In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes.  In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.

The Company's brain health focus includes Alzheimer's disease, Huntington's disease, multiple sclerosis, Parkinson's disease, behavioural health, child and adolescent mental health.

More information is available on www.ixico.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHUWANRBVAURAR